ClinicalTrials.gg
CompletedNCT00367432Updated Nov 13, 2020Results posted

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

A Phase 3 interventional study of Levetiracetam in Epilepsies and Partial, sponsored by UCB Japan Co. Ltd.. Completed at 53 sites in Japan. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-11-13.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
398
Allocation
Not applicable
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
7th of 60
398 · median 94
Started
2006
with 4 others
Phase 3
28 of 60
2 open now
Registered
17th of 60
by date
Lead sponsor
7 of 60
UCB Japan Co. Ltd.

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 7th largest by enrollment, is one of 5 that started in 2006, is one of 28 in phase 3, and was the 17th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 [NCT00160165] or N01221 [NCT00280696].

03

Conditions studied

  • Epilepsies
  • Partial

Browse trials for

Keywords

  • Epilepsies
  • Partial
  • Keppra
  • levetiracetam
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who participated in study N01221 [NCT00280696] and completed the evaluation period and transition period or patients who participated in study N01020 [NCT00160615]

Exclusion criteria

Exclusion Criteria:

  • Female patients during pregnancy, delivery and lactation, or suspected of pregnancy
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
398 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).

    Drug: Levetiracetam

Interventions

  • Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted)

    An Adverse Event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with the pharmaceutical product. Occurrence of treatment-emergent AEs is reported by the number of subjects with at least one treatment-emergent AE.

    Time frame: During the study period from Visit 1 (Week 0) to the Follow-up Visit (up to Month 60) until the time of approval granted

Secondary outcomes

  1. Change From Baseline in N01221 [NCT00280696] in Partial (Type 1) Seizure Frequency Per Week During the First 16-week Period in This Study

    The change in partial (type 1) seizure frequency from Baseline is given as a percent reduction computed as: \[ Weekly partial seizure frequency (Baseline)- Weekly partial seizure frequency (Evaluation Period)\]/ \[Weekly partial seizure frequency (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

    Time frame: Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study

  2. Seizure Frequency Per Week in Partial Seizures During the First 16-week Period in This Study

    Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

    Time frame: First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 ( Week 16)

  3. Response Status (Patients With a Percent Reduction in Partial Seizure Frequency of at Least 50% During the First 16-week Period in This Study From Baseline in N01221)

    The percent reduction from Baseline was computed as: \[ Weekly seizure frequency (Baseline)- Weekly seizure frequency (Evaluation Period)\]/ \[Weekly seizure frequency (Baseline)\] x 100. Responders are those patients with a percent reduction in partial seizure frequency of at least 50% from Baseline to first Evaluation Period in partial seizure frequency per week. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

    Time frame: Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study

  4. Change From Baseline in N01221 [NCT00280696] in Simple Partial Seizure Frequency Per Week During the First 16-week Period in This Study

    Change in simple partial seizure frequency is given as a percent reduction computed as: \[ Weekly simple partial seizure frequency (Baseline)- Weekly simple partial seizure frequency (Evaluation Period)\]/ \[Weekly simple partial seizure frequency (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

    Time frame: Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study

  5. Change From Baseline in N01221 [NCT00280696] in Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study

    Change in complex partial seizure frequency is given as a percent reduction computed as: \[ Weekly complex partial seizure frequency (Baseline)- Weekly complex partial seizure frequency (Evaluation Period)\]/ \[Weekly complex partial seizure frequency (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

    Time frame: Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study

  6. Change From Baseline in N01221 [NCT00280696] in Secondary Generalized Seizure Frequency Per Week During the First 16-week Period in This Study

    Change in secondary generalized seizure frequency is given as a percent reduction computed as: \[ Weekly sec. generalized seizure frequency (Baseline)- Weekly sec. generalized seizure frequency (Evaluation Period)\]/ \[Weekly sec. generalized seizure frequency (Baseline)\] x 100. Positive values in reduction means the value decreased from Baseline during the first 16-week Period. Secondary generalized seizures belong to one of the 3 groups: * Simple partial sz evolving to gen sz * Complex partial sz evolving to gen sz * Simple partial sz evolving to Complex partial sz evolving to gen sz

    Time frame: Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study

  7. Change From Baseline in N01221 [NCT00280696] in Simple and Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study

    Change in simple and complex partial seizure frequency is given as a percent reduction computed as (simple and complex partial seizure frequency := A): \[ Weekly A (Baseline)- Weekly A (Evaluation Period)\]/ \[Weekly A (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

    Time frame: Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study

  8. Change From Baseline in N01221 [NCT00280696] in Other Types of Seizure Frequency Per Week During the First 16-week Period in This Study

    Change in other types of seizure frequency is given as a percent reduction computed as (other types of seizure frequency:= B): \[ Weekly B (Baseline)- Weekly B (Evaluation Period)\]/ \[Weekly B (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Other types of Seizures are all seizures except Partial Seizures (Type 1).

    Time frame: Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study

07

Results

Posted Jan 16, 2012

Participant flow

The Full Analysis Set (FAS) includes all subjects to whom the investigational products are assigned after registration, excluding those with serious Good Clinical Practice violations , subjects not administered the investigational products and subjects for whom no data is available after assignment of the investigational products.

First Period (16 Weeks)
Participant flow — First Period (16 Weeks)
MilestoneLevetiracetam N01221 [NCT00280696]Levetiracetam N01020 [NCT00160615]
Started3130
Completed2750
Not completed380
Withdrew: Adverse event60
Withdrew: Lack of efficacy240
Withdrew: Withdrawal by subject60
Withdrew: Other reason20
Second Period (up to 54 Months)
Participant flow — Second Period (up to 54 Months)
MilestoneLevetiracetam N01221 [NCT00280696]Levetiracetam N01020 [NCT00160615]
Started27585
Completed18869
Not completed8716
Withdrew: Adverse event143
Withdrew: Lack of efficacy595
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject85
Withdrew: Other reason62

Outcome measures

PrimaryOccurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted)

An Adverse Event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with the pharmaceutical product. Occurrence of treatment-emergent AEs is reported by the number of subjects with at least one treatment-emergent AE.

Time frame:
During the study period from Visit 1 (Week 0) to the Follow-up Visit (up to Month 60) until the time of approval granted
Reported as:
Number · participants
Occurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted)
participantsLevetiracetam
Occurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted)381
SecondaryChange From Baseline in N01221 [NCT00280696] in Partial (Type 1) Seizure Frequency Per Week During the First 16-week Period in This Study

The change in partial (type 1) seizure frequency from Baseline is given as a percent reduction computed as: \[ Weekly partial seizure frequency (Baseline)- Weekly partial seizure frequency (Evaluation Period)\]/ \[Weekly partial seizure frequency (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

Time frame:
Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study
Reported as:
Median · Percent Reduction
Change From Baseline in N01221 [NCT00280696] in Partial (Type 1) Seizure Frequency Per Week During the First 16-week Period in This Study
Percent ReductionLevetiracetam
Change From Baseline in N01221 [NCT00280696] in Partial (Type 1) Seizure Frequency Per Week During the First 16-week Period in This Study22.00 ± 53.04
SecondarySeizure Frequency Per Week in Partial Seizures During the First 16-week Period in This Study

Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

Time frame:
First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 ( Week 16)
Reported as:
Median · Seizures Per Week
Seizure Frequency Per Week in Partial Seizures During the First 16-week Period in This Study
Seizures Per WeekLevetiracetam
Seizure Frequency Per Week in Partial Seizures During the First 16-week Period in This Study2.13 ± 7.32
SecondaryResponse Status (Patients With a Percent Reduction in Partial Seizure Frequency of at Least 50% During the First 16-week Period in This Study From Baseline in N01221)

The percent reduction from Baseline was computed as: \[ Weekly seizure frequency (Baseline)- Weekly seizure frequency (Evaluation Period)\]/ \[Weekly seizure frequency (Baseline)\] x 100. Responders are those patients with a percent reduction in partial seizure frequency of at least 50% from Baseline to first Evaluation Period in partial seizure frequency per week. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

Time frame:
Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study
Reported as:
Number · Participants
Response Status (Patients With a Percent Reduction in Partial Seizure Frequency of at Least 50% During the First 16-week Period in This Study From Baseline in N01221)
ParticipantsLevetiracetam
Responders74
Non-responders239
SecondaryChange From Baseline in N01221 [NCT00280696] in Simple Partial Seizure Frequency Per Week During the First 16-week Period in This Study

Change in simple partial seizure frequency is given as a percent reduction computed as: \[ Weekly simple partial seizure frequency (Baseline)- Weekly simple partial seizure frequency (Evaluation Period)\]/ \[Weekly simple partial seizure frequency (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

Time frame:
Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study
Reported as:
Median · Percent Reduction
Change From Baseline in N01221 [NCT00280696] in Simple Partial Seizure Frequency Per Week During the First 16-week Period in This Study
Percent ReductionLevetiracetam
Change From Baseline in N01221 [NCT00280696] in Simple Partial Seizure Frequency Per Week During the First 16-week Period in This Study39.84 ± 139.32
SecondaryChange From Baseline in N01221 [NCT00280696] in Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study

Change in complex partial seizure frequency is given as a percent reduction computed as: \[ Weekly complex partial seizure frequency (Baseline)- Weekly complex partial seizure frequency (Evaluation Period)\]/ \[Weekly complex partial seizure frequency (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

Time frame:
Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study
Reported as:
Median · Percent Reduction
Change From Baseline in N01221 [NCT00280696] in Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study
Percent ReductionLevetiracetam
Change From Baseline in N01221 [NCT00280696] in Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study20.59 ± 85.94
SecondaryChange From Baseline in N01221 [NCT00280696] in Secondary Generalized Seizure Frequency Per Week During the First 16-week Period in This Study

Change in secondary generalized seizure frequency is given as a percent reduction computed as: \[ Weekly sec. generalized seizure frequency (Baseline)- Weekly sec. generalized seizure frequency (Evaluation Period)\]/ \[Weekly sec. generalized seizure frequency (Baseline)\] x 100. Positive values in reduction means the value decreased from Baseline during the first 16-week Period. Secondary generalized seizures belong to one of the 3 groups: * Simple partial sz evolving to gen sz * Complex partial sz evolving to gen sz * Simple partial sz evolving to Complex partial sz evolving to gen sz

Time frame:
Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study
Reported as:
Median · Percent Reduction
Change From Baseline in N01221 [NCT00280696] in Secondary Generalized Seizure Frequency Per Week During the First 16-week Period in This Study
Percent ReductionLevetiracetam
Change From Baseline in N01221 [NCT00280696] in Secondary Generalized Seizure Frequency Per Week During the First 16-week Period in This Study76.56 ± 249.71
SecondaryChange From Baseline in N01221 [NCT00280696] in Simple and Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study

Change in simple and complex partial seizure frequency is given as a percent reduction computed as (simple and complex partial seizure frequency := A): \[ Weekly A (Baseline)- Weekly A (Evaluation Period)\]/ \[Weekly A (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.

Time frame:
Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study
Reported as:
Median · Percent Reduction
Change From Baseline in N01221 [NCT00280696] in Simple and Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study
Percent ReductionLevetiracetam
Change From Baseline in N01221 [NCT00280696] in Simple and Complex Partial Seizure Frequency Per Week During the First 16-week Period in This Study20.71 ± 63.01
SecondaryChange From Baseline in N01221 [NCT00280696] in Other Types of Seizure Frequency Per Week During the First 16-week Period in This Study

Change in other types of seizure frequency is given as a percent reduction computed as (other types of seizure frequency:= B): \[ Weekly B (Baseline)- Weekly B (Evaluation Period)\]/ \[Weekly B (Baseline)\] x 100. Positive values in percent reduction means that the value has decreased from Baseline during the first 16-week Period. Other types of Seizures are all seizures except Partial Seizures (Type 1).

Time frame:
Baseline in N01221 [NCT00280696], the First 16-week Evaluation Period from Visit 1 (Week 0) to Visit 5 (Week 16) in this study
Reported as:
Median · Percent Reduction
Change From Baseline in N01221 [NCT00280696] in Other Types of Seizure Frequency Per Week During the First 16-week Period in This Study
Percent ReductionLevetiracetam
Change From Baseline in N01221 [NCT00280696] in Other Types of Seizure Frequency Per Week During the First 16-week Period in This Study66.47 ± 71.28

Adverse events

Collected over Adverse Events (AEs) were collected up to 60 months from Visit 1 (Week 0) over the First and Second Period until Down-titration and Follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—64/398 (16.1%)369/398 (92.7%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventLevetiracetam
EpilepsyNervous system disorders5/398
Status EpilepticusNervous system disorders5/398
PneumoniaInfections and infestations4/398
Anticonvulsant ToxicityInjury, poisoning and procedural complications3/398
Skin LacerationInjury, poisoning and procedural complications3/398
Abortion InducedSurgical and medical procedures2/398
Anticonvulsant Drug Level IncreasedInvestigations2/398
PyrexiaGeneral disorders2/398
Abortion CompletePregnancy, puerperium and perinatal conditions1/398
Acute PsychosisPsychiatric disorders1/398
Most frequent other events
Showing 10 of 39
Most frequent other events
EventLevetiracetam
NasopharyngitisInfections and infestations308/398
SomnolenceNervous system disorders159/398
ContusionInjury, poisoning and procedural complications110/398
HeadacheNervous system disorders96/398
DiarrhoeaGastrointestinal disorders69/398
DizzinessNervous system disorders63/398
PyrexiaGeneral disorders52/398
ExcoriationInjury, poisoning and procedural complications52/398
EczemaSkin and subcutaneous tissue disorders47/398
ConstipationGastrointestinal disorders45/398

Baseline characteristics

Age, Continuous
Age, Continuous(years)Levetiracetam
Mean33.68 ± 11.18
Age, Customized
Age, Customized(participants)Levetiracetam
Between 16 and 65 years398
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam
Female196
Male202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levetiracetam
Japanese396
Asian (other than Japanese)2
Region of Enrollment
Region of Enrollment(participants)Levetiracetam
Japan398
Weight
Weight(Kilogram (kg))Levetiracetam
Mean60.39 ± 13.64
08

Study locations

53 sites
  • Aichi-gun, Aichi, Japan
  • Nagoya, Aichi, Japan
  • Hirosaki, Aomori, Japan
  • Matsudo, Chiba, Japan
  • Kitakyusyu, Fukuoka, Japan
  • Koga, Fukuoka, Japan
  • Kurume, Fukuoka, Japan
  • Fukuyama, Hiroshima, Japan
  • Asahikawa, Hokkaido, Japan
  • Hakodate, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Kobe, Hyogo, Japan
  • Kahoku-gun, Ishikawa, Japan
  • Kanazawa, Ishikawa, Japan
  • Zentsuji, Kagawa, Japan
  • Koshi, Kumamoto, Japan
  • Tsu, Mie, Japan
  • Iwanuma, Miyagi, Japan
  • Sendai, Miyagi, Japan
  • Omura, Nagasaki, Japan
  • Kashihara, Nara, Japan
  • Nagaoka, Niigata, Japan
  • Beppu, Oita, Japan
  • Izumi, Osaka, Japan
  • Neyagawa, Osaka, Japan
  • Suita, Osaka, Japan
  • Takatsuki, Osaka, Japan
  • Iruma-gun, Saitama, Japan
  • Shimotsuga-gun, Tochigi, Japan
  • Shimotsuke, Tochigi, Japan
  • Komatsushima, Tokushima, Japan
  • Chiyoda-Ku, Tokyo, Japan
  • Kodaira, Tokyo, Japan
  • Kokubunji, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Taito-ku, Tokyo, Japan
  • Ube, Yamaguchi, Japan
  • Aomori, Japan
  • Chiba, Japan
  • Fukuoka, Japan
  • Fukushima, Japan
  • Gifu, Japan
  • Hiroshima, Japan
  • Kagoshima, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Miyazaki, Japan
  • Niigata, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Shizuoka, Japan
  • Toyama, Japan
  • Yamagata, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2006
First posted
Aug 22, 2006
Start
Jul 2006
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Jan 16, 2012
Last update
Nov 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00367432
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Aug 22, 2006
Start date
Jul 2006
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Jan 16, 2012
Last update
Nov 13, 2020

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion